Haiying Tang1, Matthew Fronheiser1, Harold Malone1, Paul Sleph2, Adrienne Pena1, Thomas Petrone1, Thomas Bradstreet1, Patrick Chow1, Lei Zhao2, David Gordon2, Feng Luo3, and Wendy Hayes1
1Bristol Myers Squibb, Princeton, NJ, United States, 2Bristol Myers Squibb, Hopewell, NJ, United States, 3Bristol Myers Squibb, Wallingford, CT, United States
Recent advances in cardiovascular
MRI (CMR) technologies such as T1-mapping or extracellular volume (ECV)
fraction (derived from T1-mapping) offer robust techniques to assess diffuse
fibrosis in patients with myocardial infarction and heart failure. In the
present study, CMR assessment of myocardial fibrosis and hypertrophy was
evaluated in an isoproterenol infusion model in Balb/c mice.
The CMR techniques including T1-mapping and the ECV quantification provide a translational
non-invasive imaging marker to assess diffuse myocardial fibrosis, and the potential to evaluate efficacy of anti-fibrosis
treatment.
